AbbVie
1 North Waukegan Road
North Chicago
Illinois
60064
United States
Tel: 1-800-255-5162
Website: http://www.abbvie.com/
Email: customerservice@abbvie.com
About AbbVie
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.
Stock Symbol: ABBV
Stock Exchange: NYSE
People. Passion. Possibilities. Those three simple words mean everything at AbbVie, where patients always come first. So do cutting-edge science and innovation, which fuel our expanding pipeline as we take on the world's toughest health challenges in oncology, immunology, liver disease, women's health and beyond. Together, we strive to make a difference for patients around the world. For more visit: www.abbvie.com.
920 articles with AbbVie
-
AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer
5/17/2019
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the Phase 3 INTELLANCE-1 study of depatuxizumab mafodotin (Depatux-M, previously known as ABT-414) in patients with newly diagnosed glioblastoma (GBM), whose tumors have EGFR (epidermal growth factor receptor) amplification, demonstrated no survival benefit for patients receiving Depatux-M at an interim analysis.
-
An Independent Data Monitoring Committee recommended the trial be stopped because of lack of survival benefit for patients receiving the drug compared to placebo.
-
AbbVie Announces US FDA Approval of VENCLEXTA® (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients
5/15/2019
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved VENCLEXTA® (venetoclax) in combination with obinutuzumab (GAZYVA®) for previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
-
Boehringer Ingelheim announces resolution of Cyltezo® patent litigation
5/14/2019
Boehringer Ingelheim announced the resolution of all intellectual property-related litigation with AbbVie concerning Cyltezo® (adalimumab-adbm) and the reference medicine Humira® (adalimumab).
-
AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim
5/14/2019
AbbVie announced that it has resolved U.S. HUMIRA litigation with Boehringer Ingelheim.
-
MC10, Inc. and AbbVie (NYSE:ABBV) Announce Clinical Trials in Multiple Sclerosis Using the BioStamp nPoint® System
5/14/2019
This innovative, patient-focused endeavor aims to explore the use of data from the nPoint® System in order to provide unique insights into MS clinical studies.
-
AbbVie to Present at the UBS Global Healthcare Conference
5/14/2019
AbbVie, a research-based global biopharmaceutical company, will participate in the UBS Global Healthcare Conference on Tuesday, May 21, 2019.
-
Under the terms of the deal, AbbVie will grant Germany-based Boehringer Ingelheim a non-exclusive license for Cyltezo, its biosimilar to Humira.
-
AbbVie to Present at the Bank of America Merrill Lynch Healthcare Conference
5/7/2019
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019
-
For those select few who achieve the role of chief executive officer of a multi-national corporation, the compensation packages are typically quite large – especially when compared to the average salaries of company employees.
-
According to a recent BioSpace survey, 93% of respondents are open to a new job for the right opportunity. Are you one of the 93%? If so, keep your eyes open for those opportunities and don't stop looking. You never know what may come your way!
-
The FDA gave the nod to AbbVie’s Mavyret for all six strains of hepatitis C in children ages 12 to 17 years. The drug was approved for adults 18 years or older in 2017.
-
European Commission Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis
4/30/2019
Approval based on results from clinical studies showing high rates of skin clearance at 16 weeks; this clearance was durable at one year with every 12-week dosing
-
AbbVie to Present New and Updated Data of Investigational Medicines for Parkinson's Disease and Multiple Sclerosis at 2019 American Academy of Neurology Annual Meeting
4/30/2019
Presentations include updates on ABBV-951, a subcutaneous infusion therapy for Parkinson's disease (PD), and elezanumab, a monoclonal antibody directed against repulsive guidance molecule A (RGMa) in multiple sclerosis (MS), among other data to be presented
-
Whenever drug companies come under criticism for the cost of their drugs, one of the defenses touted is that only about one in 10 drugs make it to market. As a broad figure, that’s probably about right, although at least one report ranks it higher, while another provides a bit more nuance.
-
NHS England will acquire hepatitis C drugs from the companies at competitive prices and work to identify patients around the country.
-
AbbVie Reports First-Quarter 2019 Financial Results
4/25/2019
Updates 2019 GAAP Diluted EPS Guidance Range to $7.26 to $7.36; Raises 2019 Adjusted Diluted EPS Guidance Range From $8.65 to $8.75 to $8.73 to $8.83, Representing Growth of 11.0 Percent at the Midpoint
-
One of the criticisms of the biopharma industry—at least in the context of drug pricing—is how much the industry as a whole spends on lobbyists. For example, last year, PhRMA, the industry lobbying group, spent more than $27.5 million on its lobbying activities.
-
Plaque psoriasis is the most common type of psoriasis, caused by overproduction of skin cells. This causes inflamed, red lesions called plaques.
-
AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI™ (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis
4/23/2019
Approval based on clinical trials showing people treated with SKYRIZI™ (risankizumab-rzaa) every 12 weeks - four doses a year after two initial doses - achieved high levels of durable skin clearance at 16 weeks and maintained this response at one year[1-3]